COMPARES mRNA AND ADENOVIRUS-BASED SARS-CoV-2 VACCINES

Authors

  • HISA FAADHILAH Bachelor Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
  • KARINA O. WISEVA Bachelor Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
  • FRIDA WIDYASTUTI Bachelor Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia
  • NASRUL WATHONI Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia

DOI:

https://doi.org/10.22159/ijap.2021.v13s4.43822

Keywords:

Vaccine, Covid-19, Effectiveness vaccine

Abstract

This review is aimed at looking at the Covid-19 vaccine, formula and comparison of mRNA (Moderna and Pfizer) and adenovirus vector (AstraZeneca) vaccines that have been circulating in terms of administration, effectiveness, safety, side effects, contraindications, and in terms of price. This review was conducted by taking some literature from a database that focuses on the Covid vaccine, the development of the Covid vaccine, the Moderna vaccine, the Pfizer vaccine, and the AstraZeneca vaccine. Three vaccines, 2 were mRNA-based vaccines (Moderna and Pfizer) and 1, namely AstraZeneca, was based on adenovirus vectors. The results obtained are from international journals with the keyword comparison of mRNA vaccine and adenovirus vector, then the results show that the comparison can be seen through the method carried out. Some vaccines have their own advantages and disadvantages. When viewed from several aspects, such as administration which has different doses. Then seen from the effectiveness of the three vaccines have a sufficient value because they are above 80%. For safety, it has passed clinical trials in humans, but there are still shortcomings in each vaccine of course. Vaccines derived from mRNA (Moderna) are the most expensive vaccines because of the highest safety.

Downloads

Download data is not yet available.

References

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8. doi: 10.1016/j.jare.2020.03.005, PMID 32257431.

Kwok KO, Li KK, Wei WI, Tang A, Wong SYS, Lee SS. Editor’s Choice: Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey. Int J Nurs Stud. 2021;114:103854. doi: 10.1016/j.ijnurstu.2020.103854, PMID 33326864.

Fauci AS, Lane HC, Redfield RR. Covid-19- navigating the uncharted. N Engl J Med. 2020;382(13):1268-9. doi: 10.1056/NEJMe2002387, PMID 32109011.

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8. doi: 10.1016/j.jare.2020.03.005, PMID 32257431.

Haque A, Pant AB. Efforts at COVID-19 vaccine development: challenges and successes. Vaccines. 2020;8(4):1-16. doi: 10.3390/vaccines8040739, PMID 33291245.

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-32. doi: 10.1038/s41577-020-00434-6, PMID 32887954.

Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, Spandidos DA, Tsatsakis A. Towards effective COVID 19 vaccines: updates, perspectives and challenges. Int J Mol Med. 2020;46(1):3-16. doi: 10.3892/ijmm.2020.4596, PMID 32377694.

Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254. doi: 10.1016/j.biopha.2021.111254.

Acuna Zegarra MA, Diaz Infante S, Baca Carrasco D. COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses. Math Biosci. 2021;337. PMID 108614.

Wibawa T. COVID-19 vaccine research and development: ethical issues. Trop Med Int Health. 2021;26(1):14-9. doi: 10.1111/tmi.13503, PMID 33012020.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232-8. doi: 10.1080/21645515.2020.1735227, PMID 32186952.

Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID 19 vaccine safety. Int J Mol Med. 2020;46(5):1599-602. doi: 10.3892/ijmm.2020.4733, PMID 33000193.

Lee N, McGeer A. The starting line for COVID-19 vaccine development. Lancet. 2020;395(10240):1815-6. doi: 10.1016/S0140-6736(20)31239-3, PMID 32473680.

Wu SC. Progress and concept for COVID-19 vaccine development. Biotechnol J. 2020;15(6):e2000147. doi: 10.1002/biot.202000147, PMID 32304139.

Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat Hum Behav. 2021;5(3):337-48. doi: 10.1038/s41562-021-01056-1, PMID 33547453.

Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-6. doi: 10.1126/science.abb8923.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577, PMID 33301246.

Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;170:1-25. doi: 10.1016/j.addr.2020.12.011, PMID 33359141.

Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. 2020;86:106717. doi: 10.1016/j.intimp.2020.106717, PMID 32585611.

Rayman MP, Calder PC. Optimizing COVID-19 vaccine efficacy by ensuring nutritional adequacy. Br J Nutr. 2021;50:1-2. doi: 10.1017/S0007114521000386, PMID 33504378.

Scialo F, Vitale M, Daniele A, Nigro E, Perrotta F, Gelzo M, Ladev IC. SARS-CoV-2: one year in the pandemic. What have we learned, the new vaccine era and the threat of SARS-CoV-2 variants 2021.

Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952-4. doi: 10.1016/S0140-6736(21)00370-6, PMID 33581803.

Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020;395(10239):1751-2. doi: 10.1016/S0140-6736(20)31252-6, PMID 32505245.

Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, Blain AE, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, MacNeil J, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K. The advisory committee on immunization practices’ interim recommendation for the use of janssen COVID-19 vaccine- United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):329-32. doi: 10.15585/mmwr.mm7009e4. PMID 33661860.

Plotkin SA. Vaccine development and implementation. Vaccin Fact. 2012;B2012:105.

Brune KD, Howarth M. New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue. Front Immunol. 2018;9:1432. doi: 10.3389/fimmu.2018.01432, PMID 29997617.

Cohen AA, Gnanapragasam PNP, Lee YE, Hoffman PR, Ou S, Kakutani LM, Keeffe JR, Wu HJ, Howarth M, West AP, Barnes CO, Nussenzweig MC, Bjorkman PJ. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. 2021;371(6530):735-41. doi: 10.1126/science.abf6840, PMID 33436524.

Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz Linek U, Moy VT, Howarth M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA. 2012;109(12):E690-7. doi: 10.1073/pnas.1115485109, PMID 22366317.

Izda V, Jeffries MA, Sawalha AH. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222. doi: 10.1016/j.clim.2020.108634.

Lee HJ, Choi JH. Tetanus–diphtheria–acellular pertussis vaccination for adults: an update. Clin Exp Vaccine Res. 2017;6(1):22-30. doi: 10.7774/cevr.2017.6.1.22, PMID 28168170.

Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi: 10.3389/fimmu. 2020.585354. PMID 33163000.

Shahcheraghi SH, Ayatollahi J, Aljabali AA, Shastri MD, Shukla SD, Chellappan DK, Jha NK, Anand K, Katari NK, Mehta M, Satija S, Dureja H, Mishra V, Almutary AG, Alnuqaydan AM, Charbe N, Prasher P, Gupta G, Dua K, Lotfi M, Bakshi HA, Tambuwala MM. An overview of vaccine development for COVID-19. Ther Deliv. 2021;12(3):235-44. doi: 10.4155/tde-2020-0129, PMID 33624533.

Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev. 2021;169:168-89. doi: 10.1016/j.addr.2020.12.006, PMID 33316346.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O’Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart Tautges R, Ledgerwood JE, Graham BS, Beigel JH, mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2- preliminary report. N Engl J Med. 2020;383(20):1920-31. doi: 10.1056/NEJMoa2022483, PMID 32663912.

Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021;7(4):512-33. doi: 10.1021/acscentsci.1c00120, PMID 34056083.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. doi: 10.1056/NEJMoa2035389, PMID 33378609.

Kaur SP, Gupta V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information; 2020.

Yang S, Hua M, Liu X, Du C, Pu L, Xiang P, Wang L, Liu J. Bacterial and fungal co-infections among COVID-19 patients in the intensive care unit. Microbes Infect. 2021;23(4-5):104806. doi: 10.1016/j.micinf.2021.104806, PMID 33684520.

WHO. Background document on the mRNA-1273 vaccine. Who; 2021. p. 2.

WHO. Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Who. 2021;2:1-44.

Vaccine AC. Astra Zeneca COVID-19 vaccine product monograph. Vol. 1. ASTRAZENECA CANADA INC; 2021. p. 1-23.

Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centreis hosted on Elsevier Connect, the company’s public news and information; 2020.

Antonelli Incalzi RI, Trevisan C, Del Signore S, Volpato S, Fumagalli S, Monzani F, Bellelli G, Gareri P, Mossello E, Malara A, Coin A, Zia G, Ranhoff AH. Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine. 2021;39(17):2325-7. doi: 10.1016/j.vaccine.2021.03.066, PMID 33810907.

Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information; 2020.

Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R. Effectiveness of the Pfizer-BioNTech and Oxford-Astra Zeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Br Med J. 2021;373.

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O’Dell S, Schmidt SD, Corbett KS, Swanson PA, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH, mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Oolder Aadults. N Engl J Med. 2020;383(25):2427-38. doi: 10.1056/NEJMoa2028436, PMID 32991794.

Middleton E. Fact sheet for healthcare providers administering vaccine (vaccination providers); 2019. p. 1-37.

Health M. Administration of Astra Zeneca COVID-19/COVISHIELD vaccine. Covishield. 2021:1-13.

Putter JS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’ s public news and information; 2020.

Knoll MD, Wonodi C. Oxford-Astra Zeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-4. doi: 10.1016/S0140-6736(20)32623-4. PMID 33306990.

Published

11-12-2021

How to Cite

FAADHILAH, H., WISEVA, K. O., WIDYASTUTI, F., & WATHONI, N. (2021). COMPARES mRNA AND ADENOVIRUS-BASED SARS-CoV-2 VACCINES. International Journal of Applied Pharmaceutics, 13(4), 77–82. https://doi.org/10.22159/ijap.2021.v13s4.43822

Issue

Section

Review Article(s)